Pazopanib Induces Retinal Tear: A Case Report

Jianqing Lin, Raza A Hasan


This is a case report about a renal cell cancer patient who developed retinal tear after anti-VEGF multi-tyrosine kinase inhibitor Pazopanib. Early recognition and referral to ophthalmology for management is necessary.


renal cell cancer; Pazopanib;Retinal Tear

Full Text:



Rini BI, Campbell SC, & Escudier B. Renal Cell Carcinoma. The Lancet. 2009, 373(9669):1119-1132

Gupta K, Miller JD, Li JZ, Russell MW, & Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treatment Reviews. 2008, 34(3):193-205

Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. The Oncologist. 2011, 16(2), 14-22

Gernone A. Experience with pazopanib in the treatment of metastatic renal cell carcinoma: a monocentric experience. Tumori. 2014, 100(4):165e-168e

Gaertner KM, Caldwell SH, & Rahma OE. A Case of Retinal Tear Associated with Use of Sorafenib. Frontier Oncology. 2014, 4:196

Wegner A, & Khoramnia R. Neurosensory retinal detachment due to sunitinib treatment. Eye. 2011, 25:1517-1518

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, & Barrios CH. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 2010, 28(6):1061-1068

Yafai Y, Yang XM, Niemeyer M, Nishiwaki A, Lange J, Wiedemann P, & King AG. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats. European Journal of Pharmacology. 2011, 666(1-3):12-18.

Takahashin K, Saishin Y, Saishin Y, King AG, Levin R, & Campochiaro PA. Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib. JAMA Opthalmology. 2009, 127(4):494-499

Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapy. 2007, 6

Chiang A, Chang L, Yu F, & Sarraf D. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina. 2008, 28(9):1265-1269

Nagiel A, Freund B, Spaide RF, Munch IC, Larsen M, & Sarraf D. Mechanism of Retinal Pigment Epithelium Tear Formation Following Intravitreal Anti–Vascular Endothelial Growth Factor Therapy Revealed by Spectral-Domain Optical Coherence Tomography. American Journal of Opthalmology. 2013, 156(6):981-988


  • There are currently no refbacks.

AJCC-REP (ISSN 2572-5742)Copyright © 2012-2021. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States